A Japanese encephalitis vaccine from India induces durable and cross-protective immunity against temporally and spatially wide-ranging global field strains

Journal of Infectious Diseases

Volumn 212, Issue 5, 2015, Pages 715-725

  Singh, Anit ^a   Mitra, Monjori ^e   Sampath, Gadey ^b   Venugopal, P ^f   Venkateswara Rao, J ^g   Krishnamurthy, B ^h   Gupta, Mukesh Kumar ^g   Sri Krishna, S ^c   Sudhakar, B ⁱ   Bhuvaneswara Rao, N ^j   Kaushik, Yashpal ^a   Gopinathan, K ^a   Hegde, Nagendra R ^d   Gore, Milind M ^k   Mohan, Krishna V ^a   Ella, Krishna M ^a  

^a Bharat Biotech International Limited   (India)

^b Institute of Preventive Medicine   (India)

^c Mahavir Hospital and Research Centre   (India)

^d Ella Foundation   (India)

^e Institute of Child Health ^*  (India)

^f King George Hospital   (India)

^g GANDHI MEDICAL COLLEGE   (India)

^h MYSORE MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

ⁱ Priya Children's Hospital   (India)

^j Sri Sreenivasa Children's Hospital   (India)

^k NATIONAL INSTITUTE OF VIROLOGY   (India)

more..

Author keywords

Cross protection; Durable immunity; Genotype; Indigenous strain; Japanese encephalitis; Vaccine

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; JENVAC; PLACEBO; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS RNA;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; COMMON COLD; COUGHING; CROSS PROTECTION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; FEMALE; FEVER; GENOTYPE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNITY; IMMUNOGENICITY; INDIA; INJECTION SITE PAIN; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; VERO CELL LINE; VIRUS STRAIN; VOMITING; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS REACTION; DNA SEQUENCE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; INFANT; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENCEPHALITIS VIRUS, JAPANESE; FEMALE; HUMANS; IMMUNITY, HETEROLOGOUS; INDIA; INFANT; JAPANESE ENCEPHALITIS VACCINES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VACCINATION; YOUNG ADULT;

EID: 84939459497     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv023     Document Type: Article

References (45)

1. Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:1-27.
2. Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011; 89:766-74.
3. Solomon T. Recent advances in Japanese encephalitis. J Neurovirol 2003; 9:274-83.
4. Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 2011; 10: 355-64.
5. Verma R. Japanese encephalitis vaccine: need of the hour in endemic states of India. Hum Vaccin Immunother 2012; 8:491-3.
6. Parida M, Dash PK, Tripathi NK, et al. Japanese encephalitis outbreak, India, 2005. Emerg Infect Dis 2006; 12:1427-30.
7. Kabilan L, Rajendran R, Arunachalam N, et al. Japanese encephalitis in India: an overview. Indian J Pediatrics 2004; 71:609-15.
8. Kedarnath N, Prasad SR, Dandawate CN, Koshy AA, George S, Ghosh SN. Isolation of Japanese encephalitis and West Nile viruses from peripheral blood of encephalitis patients. Indian J Med Res 1984; 79:1-7.
9. Hegde NR, Kumar D, Rao PP, et al. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India. Vaccine 2014; 32:3636-43.
10. Abe M, Kuzuhara S, Kino Y. Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells. Vaccine 2003; 21:1989-94.
11. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005; 23:5205-11.
12. Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. Clin Infect Dis 2010; 50:1155-64.
13. Jones T. A chimeric live attenuated vaccine against Japanese encephalitis. Expert Rev Vaccines 2004; 3:243-8.
14. Kuzuhara S, Nakamura H, Hayashida K, et al. Non-clinical and Phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 2003; 21:4519-26.
15. Lyons A, Kanesa-thasan N, Kushner RA, et al. A phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007; 25:3445-53.
16. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a noninferiority, Phase III, randomized controlled trial. Lancet 2007; 370: 1847-53.
17. Dubischar-Kastner K, Eder S, Buerget V, et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010; 28:5197-202.
18. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008; 26:4382-6.
19. Eder S, Dubischar-Kastner K, Firbas C, et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®. Vaccine 2011; 29:2607-12.
20. Tsarev SA, Sanders ML, Vaughn DW, Innis BL. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 2000; 18(suppl. 2):36-43.
21. Fan Y-C, Chen J-M, Chiu H-C, et al. Partially neutralizing potency against emerging genotype I virus among children receiving formalin-inactivated Janapese encephalitis virus vaccine. PLoS Negl Trop Dis 2012; 6:e1834.
22. Erra EO, Askling HH, Rombo L, et al. A single dose of Vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travellers primed with mouse brain-derived JE vaccines. Clin Infect Dis 2012; 55:825-34.
23. Bonaparte M, Dweik B, Feroldi E, et al. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India. BMC Infect Dis 2014; 14:156.
24. Erra EO, Askling HH, Yoksan S, et al. Cross-protection elicited by primary and booster vaccination against Japanese encephalitis: a two-year follow-up study. Vaccine 2014; 32:119-23.
25. Schuh AJ, Ward MJ, Leigh Brown AJ, Barrett AD. Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia. J Virol 2014; 88:4522-32.
26. Han N, Adams J, Chen P, et al. Comparison of genotypes I and III in Japanese encephalitis virus reveals distinct differences in their genetic and host diversity. J Virol 2014; 88:11469-79.
27. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2-to 5-year-olds and naïve 12-to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 2010; 29:1111-7.
28. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188:1213-30.
29. Beasley DW, Li L, Suderman MT, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004; 22:3722-6.
30. Li MH, Fu SH, Chen WX, et al. Genotype V Japanese encephalitis virus is emerging. PLoS Negl Trop Dis 2011; 5:e1231.
31. Erra EO, Askling HH, Yoksan S, et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis 2013; 56:267-70.
32. Takhampunya R, Kum HC, Tippayachai B, et al. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. Virol J 2011; 8:449.
33. Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28:834-9.
34. Vashishtha VM, Kalra A, Bose A, et al. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization. Indian Pediatr 2013; 50:1095-108.
35. Indian Council of Medical Research. Minutes of the meeting of the Core Committee on Vaccines. http://www.icmr.nic.in/minutes/Minutes%20Core%20Committee%20on%20Vaccines.pdf. Accessed 28 November 2014.
36. Murhekar MV, Ranjan P, Selvaraju S, Pandey A, Gore MM, Mehendale SM. Low coverage and acceptable effectiveness of single dose of Japanese encephalitis vaccine, Gorakhpur division, Uttar Pradesh, India. J Infect 2014; 69:517-20.
37. Ranjan P, Gore M, Selvaraju S, Kushwaha KP, Srivastava DK. Changes in acute encephalitis syndrome incidence after introduction of Japanese encephalitis vaccine in a region in India. J Infect 2014; 69:200-2.
38. Wang Y, Dong D, Cheng G, Zuo S, Liu D, Du X. Post-marketing surveillance of live-attenuated Japanese encephalitis vaccine safety in China. Vaccine 2014; 32:5875-9.
39. Liu Y, Lin H, Zhu Q, Wu C, Zhao Z, Zheng H. Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005-2012. Vaccine 2014; 26:1768-73.
40. Kumar KR, Basha R, Harish BR, et al. A coverage evaluation survey of JE vaccination in two districts of Karnataka. J Commun Dis 2010; 42:179-84.
41. Raghunath BG, Hiremath SG. Adverse events following immunisation with SA 14-14-2 Japanese encephalitis vaccine in children of Kolar, Karnataka. J Indian Med Assoc 2012; 110:10-2.
42. Directorate of National Vector Borne Disease Control Programme, Government of India, New Delhi. Details of AES/JE cases and deaths from 2008-2014. http://www.nvbdcp.gov.in/Doc/je-aes-till-June14.pdf. Accessed 26 September 2014.
43. National Commission for Protection of Child Rights, Government of India, New Delhi. Strengthening health institutions for child health: NCPCR interventions, Aug 2012-October 2013. Part II. Strengthening of public health services in Gorakhpur region for children with JE/AES. http://ncpcr.gov.in/showfile.php?lang=1&level=3&&sublinkid=432&lid=870. Accessed 26 September 2014.
44. Bandyopadhyay B, Bhattacharya I, Adhikary S, et al. Incidence of Japanese encephalitis among acute encephalitis syndrome cases in West Bengal, India. Biomed Res Int 2013; doi:10.1155/2013/896749.
45. Jain P, Jain A, Kumar A, et al. Epidemiology and etiology of acute encephalitis syndrome in North India. Jpn J Infect Dis 2014; 67: 197-203.